bausch and lomb corp is a renewables and environment company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.
Company profile
Ticker
BLCO
Exchange
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Bausch & Lomb Argentina S.R.L. • Waicon Vision S.A. • AcuFocus Australia • Bausch & Lomb (Australia) Pty Ltd • Bausch & Lomb Australia Holdings Pty Ltd. • BAUSCH HEALTH LLC • Bausch & Lomb Pharma S.A. • BL Indústria Ótica Ltda. • Beijing Bausch & Lomb Eyecare Company Ltd • Shandong Bausch & Lomb Freda New Packaging Materials Co., Ltd. ...
BLCO stock data
Latest filings (excl ownership)
8-K
Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors
28 Feb 24
10-K
2023 FY
Annual report
21 Feb 24
8-K
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and
21 Feb 24
8-K/A
Financial Statements and Exhibits
13 Nov 23
8-K/A
Departure of Directors or Certain Officers
7 Nov 23
10-Q
2023 Q3
Quarterly report
1 Nov 23
8-K
Bausch + Lomb Announces Third-Quarter 2023 Results
1 Nov 23
8-K
Poised for Significant Growth in Prescription Dry Eye Segment
29 Sep 23
8-K
Bausch + Lomb Announces Pricing of Senior Secured Notes Offering
14 Sep 23
8-K
Other Events
11 Sep 23
Transcripts
BLCO
Earnings call transcript
2023 Q4
21 Feb 24
BLCO
Earnings call transcript
2023 Q3
1 Nov 23
BLCO
Earnings call transcript
2023 Q2
2 Aug 23
BLCO
Earnings call transcript
2023 Q1
3 May 23
BLCO
Earnings call transcript
2023 Q1
3 May 23
BLCO
Earnings call transcript
2022 Q4
22 Feb 23
BLCO
Earnings call transcript
2022 Q3
2 Nov 22
BLCO
Earnings call transcript
2022 Q2
7 Aug 22
BLCO
Earnings call transcript
2022 Q1
8 Jun 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 360.00 mm | 360.00 mm | 360.00 mm | 360.00 mm | 360.00 mm | 360.00 mm |
Cash burn (monthly) | 10.67 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 72.43 mm | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 287.57 mm | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 27.0 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 87 |
Opened positions | 16 |
Closed positions | 8 |
Increased positions | 23 |
Reduced positions | 22 |
13F shares | Current |
---|---|
Total value | 714.39 bn |
Total shares | 352.90 mm |
Total puts | 245.90 k |
Total calls | 311.40 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
BHC Bausch Health Companies | 310.45 mm | $0.00 |
FIL | 7.26 mm | $123.05 bn |
Eminence Capital | 5.99 mm | $101.61 bn |
Goldentree Asset Management | 5.07 mm | $85.87 bn |
Icahn Carl C Et Al | 3.50 mm | $59.32 bn |
Maple Rock Capital Partners | 3.22 mm | $54.58 bn |
Citadel Advisors | 1.77 mm | $29.96 bn |
River Road Asset Management | 1.59 mm | $27.03 bn |
Alberta Investment Management | 1.35 mm | $22.91 bn |
Freshford Capital Management | 1.35 mm | $22.90 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Mar 24 | Schutter Richard U De | Common Shares, No Par Value | Grant | Acquire A | No | No | 17.3 | 1,553 | 26.87 k | 32,952 |
29 Mar 24 | Paulson John | Common Shares, No Par Value | Grant | Acquire A | No | No | 17.3 | 1,264 | 21.87 k | 31,538 |
29 Mar 24 | Robertson Russel C | Common Shares, No Par Value | Grant | Acquire A | No | No | 17.3 | 1,481 | 25.62 k | 25,906 |
1 Mar 24 | Sam Eldessouky | Common Shares, No Par Value | Payment of exercise | Dispose F | No | No | 16.47 | 4,854 | 79.95 k | 243,780 |
1 Mar 24 | Yehia Hashad | Common Shares, No Par Value | Payment of exercise | Dispose F | No | No | 16.47 | 2,143 | 35.30 k | 102,271 |
News
RBC Capital Maintains Outperform on Bausch & Lomb, Lowers Price Target to $18
22 Apr 24
Evercore ISI Group Maintains In-Line on Bausch & Lomb, Raises Price Target to $17
4 Apr 24
Barclays Maintains Equal-Weight Rating for Bausch & Lomb: Here's What You Need To Know
26 Feb 24
Barclays Maintains Equal-Weight on Bausch & Lomb, Raises Price Target to $18
26 Feb 24
Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
21 Feb 24
Press releases
Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs
18 Apr 24
Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1
15 Apr 24
Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting
27 Mar 24
Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors
28 Feb 24
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance
21 Feb 24